EP1468085B1 - Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis - Google Patents
Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis Download PDFInfo
- Publication number
- EP1468085B1 EP1468085B1 EP03702506A EP03702506A EP1468085B1 EP 1468085 B1 EP1468085 B1 EP 1468085B1 EP 03702506 A EP03702506 A EP 03702506A EP 03702506 A EP03702506 A EP 03702506A EP 1468085 B1 EP1468085 B1 EP 1468085B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oligopeptide
- sequence
- amino acid
- metastasis
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010027476 Metastases Diseases 0.000 title claims abstract description 42
- 230000009401 metastasis Effects 0.000 title claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 25
- 230000009400 cancer invasion Effects 0.000 title abstract description 14
- 230000002265 prevention Effects 0.000 title description 5
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 137
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 137
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 23
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 23
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 22
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 22
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 22
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- 230000001575 pathological effect Effects 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 54
- 230000004709 cell invasion Effects 0.000 claims description 31
- 125000000539 amino acid group Chemical group 0.000 claims description 23
- 230000000903 blocking effect Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 230000001225 therapeutic effect Effects 0.000 abstract description 15
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 29
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 25
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 230000009545 invasion Effects 0.000 description 15
- 108010082117 matrigel Proteins 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000008986 metabolic interaction Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- -1 t-butoxycarbonyl Chemical group 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to synthetic peptides that exhibit inhibitory activity towards cancer invasion and metastasis.
- the peptides of the invention comprises the sequence PRKPKWDK (SEQ ID No. 2) corresponding to amino acids 85 to 92 of the matrix metalloproteinase-2 (MM P-2), and fragments, analogs and homologs of SEQ ID No. 2.
- the invention also relates to the uses of such peptides for inhibiting human cancer invasion and metastasis and further to the therapeutic use in preventing and treating cancer and other pathological conditions related to the degradation of extracellular matrix by MMPs.
- MMPs matrix metalloproteinases
- ECM extracellular matrix
- MMP-1 MMP-2
- MMP-3 MMP-8
- MMP-9 MMP-13
- MMP-2 is implicated in primary tumour growth as well as in tumour metastasis.
- This particular MMP is able to digest collagen and other extracellular matrix (ECM) proteins as a precondition for the spreading of cancer for its invasion and metastasis.
- ECM extracellular matrix
- the present invention embodies synthetic peptides which can effectively block cancer cell invasion.
- the scope of the invention is defined by the appended claims.
- the benefits of these agents and the antibodies to them are the utility in clinical applications for blocking cancer invasion and metastasis.
- An object of the present invention is to provide a synthetic oligopeptide having the amino acid sequence analogous to specific amino sequence of the matrix metalloproteinase 2 sequence (85-92) that is effective in blocking cancer invasion and cancer metastasis.
- An object of the present invention is to provide synthetic peptides that are useful in blocking cancer invasion and metastasis having an amino acid sequence PRKPKWDK (SEQ ID No. 2) or LPPDVQRVD (SEQ ID No. 6).
- Another object of the present invention is a process of utilizing synthetic peptides as disclosed in this application to prevent and treat cancer diseases. It is a further aspect of the embodiment that an effective amount of synthetic peptides is used to achieve blockade of cancer invasion and metastasis.
- Another object of the present invention provides an oligopeptide having PRKPKWDK (SEQ ID No. 2).
- the oligopeptide is of about 6 to about 20 residues. Most preferably, the oligopeptide is of about 8 to about 10 residues.
- the concentration of the synthetic peptide ranges from 1 ⁇ M to 500 ⁇ M. Most preferably, the concentration of synthetic peptides ranges from 50 ⁇ M to 200 ⁇ M.
- Another object of the present invention is an immunogenic oligopeptide that is included in pharmaceutical compositions comprising a pharmaceutically acceptable carrier and the oligopeptides.
- the oligopeptide can be used as a vaccine.
- the pharmaceutical composition comprising oligopeptide can be used to induce an immune response against a protein comprising an epitope having the sequence of the oligopeptide (e.g., SEQ ID No. 2).
- compositions and processes be accomplished both in vivo and in vitro.
- the present invention provides a synthetic oligopeptide having an amino acid sequence analogous to human MMP-2.
- the present invention further provides a modification of oligopeptides that block cancer cell invasion and metastasis by omitting one or more of the amino residues at the N-terminal end.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by omitting one or more amino acid residues at the C-terminal end.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by omitting one or more amino acid residues at the N-terminal and the C-terminal end.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by substituting one or more of the amino acid residues within the given sequence without consideration of charge and polarity of the substitution residue.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by substituting one or more of the amino acid residues within the given sequence with amino acid residues with similar charge and/or polarity.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by omitting one or more amino acid residues within the given sequence.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by two or more of the modifications.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by repeating the oligopeptides sequence one or more times each of them covalently bound to one or more oligopeptides repeat(s).
- Another object of the present invention is using the synthetic peptides as an immunogen to generate antibodies so that such generated antibodies can effectively block cancer invasion and metastasis.
- the present invention provides a preventive or therapeutic use of one or more of the oligopeptides to directly and competitively reduce or block the metabolic action or interaction of MMP-2 by intravenous application or in another therapeutically acceptable way.
- the present invention provides a preventive or therapeutic use of one or more of the oligopeptides to indirectly reduce or block the metabolic action or interaction of MMPs by applying them as vaccines by subcutaneous application or in another acceptable way to stimulate a specific immune response which can partially or completely block the metabolic interaction of MMP-5.
- a preferred embodiment includes MMP-2.
- the present invention provides a preventive and therapeutic use of one or more of the oligopeptides where the oligopeptides are coupled to haptens to enhance immune response and thereby therapeutic efficacy.
- the present invention provides a preventive or therapeutic use of one or more of the oligopeptides to function as feed-back regulators to specifically prevent or reduce the synthesis rate of MMP-2 proteins at the cellular level.
- the present invention provides one or more oligopeptides that can block cancer cell invasion and metastasis as vaccines for the production of specific antibodies for the diagnosis of a disease involving MMP-2 or the clinical monitoring of the progression or regression of this disease.
- the present invention provides the use of one or more oligopeptides that block cancer cell invasion and metastasis for the prevention or therapy of cancer.
- the present invention provides the use of one or more oligopeptides that block cancer cell invasion and metastasis, where these oligopeptides can be applied to a patient as a vaccine, as injections, infusions, inhalations, suppositories or other pharmaceutically acceptable carriers and/or means of delivery.
- peptide refers to organic compounds comprising two or more amino acids covalently joined by peptide bonds; peptides may be a dipeptide (which contains two amino acid residues), a tripeptide (three amino acids) etc..
- oligopeptide refers to a peptide that contains typically less than 30 residues in length.
- the length of oligopeptides is not critical to the invention so long as the correct epitope is maintained.
- the oligopeptide can be as small as possible while still maintaining substantially all the biological activity of the large oligopeptide and that it is effective in blocking cancer cell invasion and metastasis.
- Oligopeptide is used interchangeable with “synthetic peptide” in this application.
- the oligopeptide used in this invention is an 'isolated” but “biologically pure” synthetic peptide.
- amino acid residues are: A (alanine); R (arginine); N (asparagine); D (aspartic acid); C (cysteine); Q (glutamine); E (glutamic acid); G (glycine); H (histidine); I (isoleucine); L (leucine); K (lysine); M (methionine); F (phenylalanine); P (proline); S (serine);T (threonine); W (tryptophan); and Y (tyrosine).
- Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a oligopeptide.
- conserveed amino acid substitutions consist of replacing one or more amino acids with amino acids with similar charge, size and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to aspartic acid (D) amino acid substitution.
- Nonconserved substitutions consist of replacing one or more amino acids with amino acids possessing dissimilar charge, size, and/or hydrophobicity, such as, for example, a glutamic acid (E) to valine (V) substitution.
- the present invention is intended to encompass conservative changes of oligopeptide with respect to substitutions, deletions, insertions or any combination thereof so long as the effectiveness of blocking cancer cell invasion and metastasis is substantially unchanged.
- oligopeptide sequences in the amino acid sequence of MMP-2 we identified possible oligopeptide sequences in the amino acid sequence of MMP-2 and found that these oligopeptide sequences effectively interfere with the functional activity of MMP-2 using in vitro invasion of ECM by cancer cells as test model.
- the present invention provides oligopeptides that can effectively block cancer cell invasion and metastasis.
- MMP-2 binds to the target ECM molecules via specific binding sites. Blocking these binding sites may therefore prevent MMP-2 from binding to its ECM substrate molecules, inhibits the destruction of the ECM and thereby prevents cancer and other diseases from spreading throughout the body.
- the present invention provides that synthetic analogs to these oligopeptides sequences are effective to prevent ECM destruction.
- One of the therapeutic oligopeptides is PRKPKWDK, which is shown to inhibit the invasion of cancer cells by about 90 %.
- the present invention additionally provides a therapeutic use of the oligopeptide in other MMP-related diseases.
- MMP-2 may use the same sites to bind to its target molecules within the ECM
- the oligopeptide disclosed in the present invention can similarly interfere other diseases.
- the preventive and therapeutic use of the synthetic oligopeptides claimed here are not limited to cancer but can also be used in cardiovascular disease and other pathological conditions associated with the destruction of the ECM by MMPs.
- These oligopeptides can be applied to a patient as a vaccine, as injections, infusions, inhalations, suppositories or other pharmaceutically acceptable carriers and/or means of delivery.
- the method of administering peptides and formulations of the present invention employs any of a number of known administrative routes such as oral, IV, subcutaneous, transcutaneous and topical administration.
- a preferred method of the present invention employs a pharmaceutical composition for parenteral administration.
- the present invention provides oligopeptides that can also be used as vaccines to raise antibodies for assays used to diagnose diseases involving MMPs (in particular, MMP-2) as well as the clinical monitoring of the progression or regression of this disease through blood assays or in other suitable diagnostic assays.
- the present invention embodies synthetic peptides effective in blocking cancer cell invasion.
- the benefits of these agents and the antibodies to them are the utility in clinical applications for preventing and treating cancer invasion and metastasis.
- synthetic oligopeptides which have the amino acid of SEQ ID No. 2 or SEQ ID No. 6 are useful in blocking cancer invasion and metastasis.
- the synthetic peptides are included in a pharmaceutical formulation for blocking cancer invasion and metastasis.
- the oligopeptide may be of about 6 to about 20 residues. Most preferably, the oligopeptide is of about 8 to about 10 residues. Most preferably, the synthetic oligopeptide contains 8 amino acid residues in length.
- the concentration of synthetic peptides ranges from 1 ⁇ M to 500 ⁇ M. Most preferably, the concentration of synthetic peptides ranges from 50 ⁇ M to 200 ⁇ M.
- Another object of the present invention is using the synthetic peptides as an immunogen to generate antibodies so that such generated antibodies can effectively block cancer invasion and metastasis.
- the synthetic oligopeptide contains 8 amino acid residues in length.
- Another object of the present invention is an immunogenic oligopeptide that is included in pharmaceutical compositions comprising a pharmaceutically acceptable carrier and the oligopeptides.
- the oligopeptide can be used as a vaccine.
- the pharmaceutical composition comprising oligopeptide can be used to induce an immune response against a protein comprising an epitope having the sequence of the oligopeptide (e.g., SEQ ID No. 2).
- compositions and processes be accomplished both in vivo and in vitro .
- the present invention provides a synthetic oligopeptide having an amino acid sequence analogous to an amino acid sequence within the protein of human MMP-2.
- the amino- and/or carboxy-termini of the synthetic oligopeptide can comprise an amino group (--NH 2 ) or a carboxy (--COOH) group, respectively.
- the oligopeptide amino-terminus may, for example, represent a hydrophobic group, including but not limited to carbobenzyl, dansyl, t-butoxycarbonyl, decanoyl, napthoyl or other carbohydrate group; an acetyl group; 9-fluorenylmethoxy-carbonyl (FMOC) group; or a modified, non-naturally occurring amino acid residue.
- the synthetic oligopeptide carboxy-terminus can, for example, represent an amido group; a t-butoxycarbonyl group; or a modified non-naturally occurring amino acid residue.
- the present invention encompasses synthetic oligopeptides that block cancer cell invasion and metastasis by omitting an amino acid residue at the N-terminal end or the C-terminal end.
- the present invention also provides a modification of oligopeptides that block cancer cell invasion and metastasis by substituting an amino acid residue within the given sequence without consideration of charge and polarity of the substitution residue.
- the present invention also contemplates peptide analogues wherein one or more amide linkage is optionally replaced with a linkage other than amide, preferably a substituted amide or an isostere of amide.
- amide linkage is optionally replaced with a linkage other than amide, preferably a substituted amide or an isostere of amide.
- amino acid residues within peptides are generally described in terms of amino acids, and preferred embodiments of the invention are exemplified by way of peptides, one having skill in the art will recognize that in embodiments having non-amide linkages, the term "amino acid” or “residue” as used herein refers to other bifunctional moieties bearing groups similar in structure to the side chains of the amino acids.
- amino acid residues may be blocked or unblocked.
- the present invention provides a modification of oligopeptides that block cancer cell invasion and metastasis by repeating the oligopeptide sequence one or more times each of them covalently bound to one or more oligopeptide repeat(s).
- the present invention provides a preventive or therapeutic use of one or more of the oligopeptides to directly and competitively reduce or block the metabolic action or interaction of MMP-2 by intravenous application or in another therapeutically acceptable way.
- the present invention provides a preventive or therapeutic use of one or more of the oligopeptides to indirectly reduce or block the metabolic action or interaction of MMPs by applying them as vaccines by subcutaneous application or in another acceptable way to stimulate a specific immune response which can partially or completely block the metabolic interaction of MMPs.
- a preferred embodiment includes MMP-2.
- the present invention provides a preventive and therapeutic use of one or more of the oligopeptides where the oligopeptides are coupled to haptens to enhance immune response and thereby therapeutic efficacy.
- the present invention provides a preventive or therapeutic use of one or more of the oligopeptides to function as feedback regulators to specifically prevent or reduce the synthesis rate of MMP-2 proteins at the cellular level.
- the present invention provides one or more oligopeptides that can block cancer cell invasion and metastasis as vaccines for the production of specific antibodies for the diagnosis of a disease involving MMP-2 or the clinical monitoring of the progression or regression of this disease.
- the present invention provides the use of one or more oligopeptides that block a human disease including, but not limited to cancer cell invasion and metastasis for the prevention or therapy of cancer; for example, prevention or therapy of infectious diseases, cardiovascular diseases and degenerative diseases.
- the present invention provides the use of one or more oligopeptides that block cancer cell invasion and metastasis for the prevention or therapy of diseases involving MMP-2.
- the present invention provides the use of one or more oligopeptides that block cancer cell invasion and metastasis, where these oligopeptides can be applied to a patient as a vaccine, as injections, infusions, inhalations, suppositories or other pharmaceutically acceptable carriers and/or means of delivery.
- compositions of the present invention may be in the form of a peptide or peptides in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, bio-compatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
- the compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.
- Pharmaceutically-acceptable carriers may also be comprised of excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, Pa .
- the pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
- the present invention provides oligopeptides that can also be used as vaccines to raise antibodies for assays used to diagnose diseases involving MMPs (in particular, MMP-2) as well as the clinical monitoring of the progression or regression of this disease through blood assays or in other suitable diagnostic assays.
- the amino acid sequence of MMP-2 regarding regions of high hydrophilicity maxima enriched with charged amino acids were identified with a software program.
- the oligopeptides of the present invention may be synthesized or prepared by techniques well known in the art (see, for example, Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman and Co.; N.Y .). The oligopeptides prepared and used in the present invention are listed in Table 1.
- oligopeptide TMRKPRCGNPDVAN which was shown to have anti-MMP-2 activity by Liotta and Associates was used as a standard reference for oligopeptides.
- Table 1 Various Oligopeptide Sequences Identified and Used In the Studies Oligopeptide Sequence Number GDVAPKTDKE SEQ ID. 1 PRKPKWDK SEQ ID. 2 EDYDRDKKY SEQ ID. 3 GRSDGLM SEQ ID. 4 NYDDDRKW SEQ ID. 5 LPPDVQRVD SEQ ID. 6 RYNEVKKKMDP SEQ ID. 7
- the identified oligopeptides were custom synthesized. They were then used for Matrigel invasion studies.
- human fibroblasts- NHDF (Clonetics) were seeded on "Matrigel" insert and were allowed to reach confluence. This was done to closely simulate the in vivo conditions surrounding the cancer cells in the body.
- the human melanoma cells A2058 were then seeded on the insert.
- Conditioned media from the fibroblast culture supplemented with various levels of chosen oligopeptide was added to the chamber. The system was incubated for about 24 hours. At the end of the period the cells on the upper surface of the insert were wiped off. The cells that had invaded the Matrigel membrane and had migrated to the lower surface of the insert were stained with "quick stain" and were counted under the microscope.
- the percent inhibition was calculated by the number of cells that failed to migrate through the membrane as compared to control ("0"Ievel of oligopeptide). The inhibitory activity of the control was considered as "0',. The media from invasion assays was saved for zymogram studies.
- MMPs matrix metalloproteinases
- oligopeptides were tested for inhibiting invasion of human melanoma cancer cells.
- the oligopeptide having the amino acid sequence PRKPKWDK showed blocking activity.
- the oligopeptide having TMRKPRCGNPDVAN showed about 11% inhibition as compared to 73% shown by PRKPKWDK ( Fig.1 ).
- Oligopeptide VI having the amino acid sequence LPPDVQRVD also had some blocking activity (i.e., about 20%). Oligopeptide"I" having the amino acid sequence GDVAPKTDKE did not show any activity up to 100 ⁇ M concentration (not shown in Fig.2 ), as against 63 % shown by PRKPKVVDK at the same concentration.
- the Matrigel membrane is analogous to ECM and the ability of cancer cells to breakthrough and migrate to the other side of the membrane represents the ability of the cancer cells to metastasize in the body.
- the oligopeptide was able to significantly reduce invasion of three different types of cancer cells. In this test system the activity was directed against ECM. We conclude that our studies therefore clearly indicate that the oligopeptide can interfere with degradation of ECM in the body and thereby adversely affect the progression of diseases in which breakdown of ECM is the basic lesion.
- the invention as defined by the claims also comprises modification (either chemical or enzymatic) of the basic sequences.
- the disclosed sequence can be a dipeptide or tripeptide.
- the disclosed sequences may be modified to include this residue at either the amino or carboxyl ends of the peptides.
- the sequences may also be chemically modified to increase their activity (e.g., amidation of the carboxyl terminus portion of a sequence).
- the peptides may be chemically modified to increase their activity (e.g., amidation of the carboxy terminus portion of a sequence or including a glycine or alanine residue at either end).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35131702P | 2002-01-23 | 2002-01-23 | |
US351317P | 2002-01-23 | ||
PCT/EP2003/000659 WO2003062413A1 (en) | 2002-01-23 | 2003-01-23 | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1468085A1 EP1468085A1 (en) | 2004-10-20 |
EP1468085B1 true EP1468085B1 (en) | 2009-03-11 |
Family
ID=27613485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03702506A Expired - Lifetime EP1468085B1 (en) | 2002-01-23 | 2003-01-23 | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
Country Status (22)
Country | Link |
---|---|
US (1) | US8012935B2 (zh) |
EP (1) | EP1468085B1 (zh) |
JP (1) | JP2005515262A (zh) |
KR (1) | KR20040077764A (zh) |
CN (2) | CN101007844A (zh) |
AT (1) | ATE425247T1 (zh) |
BR (1) | BR0302819A (zh) |
CA (1) | CA2472775A1 (zh) |
DE (1) | DE60326539D1 (zh) |
EE (1) | EE200400030A (zh) |
ES (1) | ES2324027T3 (zh) |
HR (1) | HRP20040732A2 (zh) |
IL (1) | IL162714A0 (zh) |
LV (2) | LV13289B (zh) |
MX (1) | MXPA04007170A (zh) |
NO (1) | NO20034146L (zh) |
NZ (1) | NZ533738A (zh) |
PL (1) | PL209827B1 (zh) |
RU (1) | RU2346043C2 (zh) |
WO (1) | WO2003062413A1 (zh) |
YU (1) | YU76403A (zh) |
ZA (1) | ZA200405328B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2856598B1 (fr) * | 2003-06-25 | 2005-10-28 | Inst Nat Sante Rech Med | Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale |
JP4911950B2 (ja) * | 2005-11-07 | 2012-04-04 | 晃 伊東 | Mmp−1の部分ペプチドを用いた癌浸潤・転移阻害薬 |
EP2403508B1 (en) * | 2009-03-06 | 2015-10-28 | Université Paris Descartes | Method of treating cancer employing gingival fibroblast conditioned medium |
US8593732B1 (en) * | 2010-01-23 | 2013-11-26 | Lightsmyth Technologies, Inc. | Partially metallized total internal reflection immersion grating |
US8003110B1 (en) * | 2011-01-24 | 2011-08-23 | Matthias W. Rath | Metalloproteinase oligopeptides and their therapeutic use |
EP2649985A1 (en) * | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
US20140017267A1 (en) * | 2012-07-13 | 2014-01-16 | Matthias W Rath | Metalloproteinase oligopeptides and their therapeutic use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5280106A (en) * | 1988-05-20 | 1994-01-18 | Liotta Lance A | Matrix metalloproteinase peptides: role in diagnosis and therapy |
GB8817075D0 (en) * | 1988-07-18 | 1988-08-24 | Raychem Ltd | Oscillation suppressor |
US5646027A (en) * | 1994-09-08 | 1997-07-08 | Warner-Lambert Company | Process for the production of gelatinase catalytic domain protein |
CA2864069A1 (en) * | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
-
2003
- 2003-01-23 CA CA002472775A patent/CA2472775A1/en not_active Abandoned
- 2003-01-23 CN CNA2007100054389A patent/CN101007844A/zh active Pending
- 2003-01-23 DE DE60326539T patent/DE60326539D1/de not_active Expired - Lifetime
- 2003-01-23 IL IL16271403A patent/IL162714A0/xx unknown
- 2003-01-23 BR BR0302819-4A patent/BR0302819A/pt not_active IP Right Cessation
- 2003-01-23 NZ NZ533738A patent/NZ533738A/xx unknown
- 2003-01-23 EE EEP200400030A patent/EE200400030A/xx unknown
- 2003-01-23 US US10/350,258 patent/US8012935B2/en not_active Expired - Fee Related
- 2003-01-23 CN CNA038026899A patent/CN1622992A/zh active Pending
- 2003-01-23 PL PL371254A patent/PL209827B1/pl not_active IP Right Cessation
- 2003-01-23 YU YU76403A patent/YU76403A/sh unknown
- 2003-01-23 AT AT03702506T patent/ATE425247T1/de active
- 2003-01-23 MX MXPA04007170A patent/MXPA04007170A/es not_active Application Discontinuation
- 2003-01-23 KR KR10-2004-7011323A patent/KR20040077764A/ko not_active Application Discontinuation
- 2003-01-23 JP JP2003562281A patent/JP2005515262A/ja active Pending
- 2003-01-23 ES ES03702506T patent/ES2324027T3/es not_active Expired - Lifetime
- 2003-01-23 EP EP03702506A patent/EP1468085B1/en not_active Expired - Lifetime
- 2003-01-23 WO PCT/EP2003/000659 patent/WO2003062413A1/en active IP Right Grant
- 2003-01-23 RU RU2004125599/13A patent/RU2346043C2/ru not_active IP Right Cessation
- 2003-09-17 NO NO20034146A patent/NO20034146L/no not_active Application Discontinuation
-
2004
- 2004-07-05 ZA ZA200405328A patent/ZA200405328B/en unknown
- 2004-08-13 HR HR20040732A patent/HRP20040732A2/hr not_active Application Discontinuation
- 2004-09-17 LV LVP-04-102A patent/LV13289B/en unknown
-
2005
- 2005-10-17 LV LVP-05-134A patent/LV13419B/lv unknown
Also Published As
Publication number | Publication date |
---|---|
US20030139345A1 (en) | 2003-07-24 |
LV13419B (en) | 2006-09-20 |
KR20040077764A (ko) | 2004-09-06 |
CA2472775A1 (en) | 2003-07-31 |
DE60326539D1 (de) | 2009-04-23 |
BR0302819A (pt) | 2004-04-27 |
YU76403A (sh) | 2006-05-25 |
NO20034146D0 (no) | 2003-09-17 |
ES2324027T3 (es) | 2009-07-29 |
PL371254A1 (en) | 2005-06-13 |
IL162714A0 (en) | 2005-11-20 |
JP2005515262A (ja) | 2005-05-26 |
WO2003062413A1 (en) | 2003-07-31 |
MXPA04007170A (es) | 2004-10-29 |
NO20034146L (no) | 2003-10-28 |
ATE425247T1 (de) | 2009-03-15 |
US8012935B2 (en) | 2011-09-06 |
CN1622992A (zh) | 2005-06-01 |
EE200400030A (et) | 2004-04-15 |
LV13289B (en) | 2005-11-20 |
CN101007844A (zh) | 2007-08-01 |
RU2004125599A (ru) | 2005-07-10 |
ZA200405328B (en) | 2006-03-29 |
PL209827B1 (pl) | 2011-10-31 |
EP1468085A1 (en) | 2004-10-20 |
HRP20040732A2 (en) | 2005-06-30 |
RU2346043C2 (ru) | 2009-02-10 |
NZ533738A (en) | 2006-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4846799B2 (ja) | 腫瘍の治療 | |
LV13419B (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
US7374898B2 (en) | Peptide inhibitors against seprase | |
EP2349312B1 (de) | N-terminal modifizierte tetrapeptidderivate mit c-terminalem argininmimetikum | |
CA2123420A1 (en) | Protease vaccine against heartworm | |
US20230158100A1 (en) | Treatment of panx1 associates diseases | |
AU2003205658A1 (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
US9617325B2 (en) | Treatment of IgE-mediated disease | |
LT5328B (lt) | Sintetiniai peptidai ir jų panaudojimas vėžio invazijos ir metastazių gydymui ir profilaktikai | |
DE102009035593A1 (de) | N-terminal modifizierte Tetrapeptidderivate mit C-terminalem Argininmetikum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040621 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RATH, MATTHIAS Inventor name: NETKE, SHRIRANG Inventor name: NIEDZWIECKI, ALEKSANDRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RATH, MATTHIAS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NETKE, SHRIRANG Inventor name: NIEDZWIECKI, ALEKSANDRA Inventor name: RATH, MATTHIAS |
|
17Q | First examination report despatched |
Effective date: 20061017 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60326539 Country of ref document: DE Date of ref document: 20090423 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20090401487 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2324027 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E005791 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090824 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090611 |
|
26N | No opposition filed |
Effective date: 20091214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100131 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20110117 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20120130 Year of fee payment: 10 Ref country code: FR Payment date: 20120206 Year of fee payment: 10 Ref country code: CH Payment date: 20120123 Year of fee payment: 10 Ref country code: IE Payment date: 20120124 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20111222 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20120120 Year of fee payment: 10 Ref country code: BE Payment date: 20120117 Year of fee payment: 10 Ref country code: IT Payment date: 20120124 Year of fee payment: 10 Ref country code: GB Payment date: 20120120 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20120125 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20090401487 Country of ref document: GR Effective date: 20120802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120802 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20120111 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120118 Year of fee payment: 10 |
|
BERE | Be: lapsed |
Owner name: RATH, MATTHIAS Effective date: 20130131 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20130801 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 425247 Country of ref document: AT Kind code of ref document: T Effective date: 20130131 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130123 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130801 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130124 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130801 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130124 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60326539 Country of ref document: DE Effective date: 20130801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130123 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20140321 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130124 |